Ani Pharmaceuticals (ANIP) Accumulated Expenses (2010 - 2026)

Ani Pharmaceuticals has disclosed Accumulated Expenses across 17 years of filings, most recently posting $27.2 million for Q2 2026.

• In Q2 2026, Accumulated Expenses fell 17.55% year-over-year to $27.2 million; the TTM figure through Jun 2026 stood at $27.2 million (down 17.55% YoY), while the FY2025 annual figure was $37.9 million, changed 0.46% from the prior year.
• Accumulated Expenses came in at $27.2 million for Q2 2026 at Ani Pharmaceuticals, up from $16.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $37.9 million in Q4 2025 to a low of $7.7 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $20.2 million, with a median of $16.1 million recorded in 2024.
• Year-over-year, Accumulated Expenses soared 134.06% in 2025 and slipped 27.83% in 2026.
• Over 5 years, Accumulated Expenses stood at $10.3 million in 2022, then surged by 130.66% to $23.8 million in 2023, then jumped by 58.6% to $37.7 million in 2024, then advanced by 0.46% to $37.9 million in 2025, then slipped by 28.35% to $27.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $27.2 million in Q2 2026, $16.1 million in Q1 2026, and $37.9 million in Q4 2025.